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N-Acetylglucosamine (O-GlcNAc) transferase (OGT) regu-
lates protein O-GlcNAcylation, an essential and dynamic post-
translationalmodification. TheO-GlcNAcmodification is pres-
ent on numerous nuclear and cytosolic proteins and has been
implicated in essential cellular functions such as signaling
and gene expression. Accordingly, altered levels of protein
O-GlcNAcylation have been associated with developmental
defects and neurodegeneration. However, mutations in the
OGT gene have not yet been functionally confirmed in humans.
Here, we report on two hemizygous mutations in OGT in indi-
viduals withX-linked intellectual disability (XLID) and dysmor-
phic features: one missense mutation (p.Arg284Pro) and one
mutation leading to a splicing defect (c.463–6T>G). Both
mutations reside in the tetratricopeptide repeats of OGT that
are essential for substrate recognition. We observed slightly
reduced levels ofOGTprotein and reduced levels of its opposing
enzyme O-GlcNAcase in both patient-derived fibroblasts, but
global O-GlcNAc levels appeared to be unaffected. Our data
suggest that mutant cells attempt to maintain global O-
GlcNAcylation by down-regulating O-GlcNAcase expres-
sion. We also found that the c.463–6T>G mutation leads to
aberrant mRNA splicing, but no stable truncated protein was
detected in the corresponding patient-derived fibroblasts.
Recombinant OGT bearing the p.Arg284Pro mutation was
prone to unfolding and exhibited reduced glycosylation activity
against a complex array of glycosylation substrates and proteo-
lytic processing of the transcription factor host cell factor 1,
which is also encoded by anXLID-associated gene.We conclude
that defects inO-GlcNAchomeostasis andhost cell factor 1 pro-
teolysis may play roles in mediation of XLID in individuals with
OGTmutations.
Protein O-GlcNAcylation is a dynamic and reversible post-
translational modification that is present on many nucleocyto-
plasmic and mitochondrial proteins (1, 2). O-GlcNAcylation
involves cycling of a single N-acetylglucosamine (O-GlcNAc)5
moiety on serine and threonine residues of a spectrum of sub-
strates, affecting their stability, activity, and subcellular local-
ization (3, 4). The transfer of O-GlcNAc is catalyzed by
O-GlcNAc transferase (OGT) (5, 6) and is modulated by
the availability of the donor substrate UDP-GlcNAc (7).
UDP-GlcNAc biosynthesis is coupled to glucose, glutamine,
and nucleotide metabolism. Concomitantly, OGT exerts a
nutrient-sensitive regulation over various cellular functions by
acting on myriad targets (8). OGT is highly conserved in meta-
zoa and consists of multiple tetratricopeptide repeats (TPRs)
on theN terminus and aC-terminal glycosyltransferase domain
(9, 10). Although TPRs are known to be involved in protein-
protein interactions, in the context of OGT they facilitate sub-
strate recognition and specificity (11). In addition to its glyco-
syltransferase activity, OGT was recently shown to have a role
in proteolytic processing of host cell factor 1 (HCF1) (12, 13), a
transcriptional co-regulator of the cell cycle (14). HCF1 is heav-
ily O-GlcNAcylated (15), but a recent study revealed that
O-GlcNAcylation and proteolytic cleavage of HCF1 by OGT
are independent processes (16). OGT activity is counteracted
by O-GlcNAcase (OGA), a hexosaminidase that specifically
removes O-GlcNAc modifications (17). It has been shown that
chemical inhibition of OGA in different human cell lines leads
to a decreased expression of OGT and an increased expression
of OGA (18), which indicates an as yet unidentifiedmechanism
of regulation to maintain global O-GlcNAc homeostasis. OGT
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has been linked to embryonic development in a number of ani-
mal models. Caenorhabditis elegans with null mutations in
ogt-1 are viable and fertile, but with metabolic defects (19). In
Drosophila, OGT is encodedby the super sex combs gene,which
is essential for Drosophila viability and segmentation (20, 21).
Knockdown of OGT in zebrafish causes impaired embryonic
growth with reduced brain size (22). Although OGT is ubiqui-
tously expressed, it is remarkably abundant in brain (9, 10).
Accordingly, O-GlcNAcylation has been linked to neuronal
function and brain development in a number of cell and animal
models (22, 23). In addition, recent studies have shown that
O-GlcNAc signaling can regulate axonal and dendritic growth
(24, 25) andAMPA receptor trafficking (26, 27), possibly affect-
ing learning andmemory processes. Also, alterations in protein
O-GlcNAcylation have been associated with neurodegenera-
tive diseases (28).
Genetic OGT variants identified in patients with X-linked
intellectual disability (XLID) have previously been document-
ed: first, in a clinical report, albeit accompanied bymutations in
MED12 (a knownXLID gene) (29), and second, in a large screen
for novel XLID genes (30). Here, we describe two patients
with intellectual disability, bearing hemizygous mutations in
OGT. By combining characterization of the O-GlcNAcylation
machinery in patient cells and characterization of the effects of
OGTXLIDmutations onOGTdual activity in vitro, we provide
preliminary evidence suggesting that effects on the O-GlcNAc
proteome and proteolytic processing of HCF1 may underpin
the observed XLID phenotypes.
Results
Clinical phenotype of two ID patients
Twomale patients showed intellectual disability and a devel-
opmental delay with an unknown cause. Cognitive testing in
patient 1, at the age of 5 years old, showed reduced intelligence
(WPPSI-III-NL, score 2;9) and delay in adaptive behavior
(VABS,score2;0).Additionalneurologicalsymptomswerepyra-
midal syndrome, mild spastic diplegia, and psychomotor retar-
dation with behavioral conduct disorder. In addition, patient 1
had an inguinal hernia. Dysmorphic features included
hypertelorism, low-set ears, a broad nose, full lips, supernu-
merary nipple, hypoplastic toe, mild retrognathia, long
and thin fingers, clinodactyly, and microcephaly (Fig. 1A).
Patient 1 showed involvement of the eyes including amblyo-
pia and possible astigmatism. He was born with a mild res-
piratory insufficiency based upon transient tachypnea of the
neonate. Cardiac screening revealed a bicuspid aortic valve.
An MRI at the age of 2 years old showed mild abnormalities
pointing toward periventricular leukomalacia (Fig. 1C), but
with a normal EEG.
Figure 1. Clinical images from patients with hemizygous OGT mutations. A, picture of patient 1, showing dysmorphic features. B, pictures of patient 2,
showing dysmorphic features. C, MRI image of patient 1, showing mild abnormalities pointing toward periventricular leukomalacia, indicated by red arrow-
heads. D, MRI image of patient 2, showing no brain abnormalities.
OGT variants in XLID
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The global developmental level of patient 2, at the age of 5.5
years old, was estimated at 1.5 years. He showed mouth hypo-
tonia with drooling and involvement of the eyes including
nystagmus, astigmatism, and high hypermetropia. Genital
abnormalities included a small phallus, and orchiopexy was
performed at the age of 3 years. His dysmorphic phenotype was
less evident, with bitemporal narrowing and metopic ridge as
main features (Fig. 1B). Upon birth, a ventricular septal defect
was detected, which closed spontaneously at a later age. An
MRI performed at the age of 3 years old showed no clear brain
abnormalities (Fig. 1D). The clinical features of the patients are
summarized in Table 1.
Identification ofmutations in OGT
Whole exome sequencing was performed in the two male
patients from unrelated families to uncover the cause of their
intellectual disability. Mutations in OGT were found in both
patients.
In patient 1, trio-sequencing and filtering forde novo variants
revealed two potential candidate genes. A heterozygous de novo
mutation was found in bromodomain-containing protein 1
(BRD1): Chr22(GRCh38): g.49,823,630CG; NM_001304808.1:
c.688GC (p.Val230Leu). In addition, a hemizygous de novo
missense variant in OGT was discovered: ChrX(GRCh38):
g.71,555,312GC; NM_181672.2: c.851GC (p.Arg284Pro)
(Fig. 2A). Arg-284 is conserved among many vertebrates and
some invertebrates such as Drosophila (supplemental Fig. S1).
In silico analysis of p.Arg284Pro in OGT predicted pathogenic-
ity of the mutation (Table 2). The heterozygous nature of the
mutation in BRD1, in addition to lower pathogenicity predic-
tions for p.Val230Leu (Table 2), made this variant less likely to
be pathogenic.
For patient 2, a gene panel for known intellectual disability
genes and de novo analysis did not reveal a potential causative
mutation. Further analysis of the exome data by filtering for
variants following an autosomal recessive or X-linked inherit-
ance showed a hemizygous variant in OGT: ChrX(GRCh38):
g.71,544,561TG; NM_181672.2: c.463–6TG. Segregation
analysis revealed that the mutation originates from a de novo
mutation in the grandmother of the patient, passed on via the
mother, who is the carrier (Fig. 2A). The thymine at position
c.463–6 is highly conserved (phyloP score of 6.93), and in silico
splicing analysis of c.463–6TG predicted an effect on the
canonical splice site. RT-PCR in patient fibroblasts showed
an additional splice variant for OGT (Fig. 2B). Sanger
sequencing showed a deletion of 69 base pairs, correspond-
ing to skipping of exon 4 caused by partial loss of the canon-
ical splice site in patient 2 (Fig. 2B). Skipping of exon 4 could
result in a truncated protein with a loss of 23 amino acids
(155–177-OGT).
Both mutations in OGT were absent in 60,000 controls
(ExAC database) (31). Thus, we have identified two XLID
patients that possess two novel mutations in OGT.
OGT XLIDmutations lead to an imbalance of O-GlcNAc
homeostasis
Given that OGT is a glycosyltransferase, we next investi-
gated the effects of the XLID mutations on globalO-GlcNAc
levels in lysates from patient-derived fibroblasts by immu-
noblotting. As controls, we used fibroblasts from an unre-
lated male neonate (control 1) and a female adult (control 2).
Using the RL2 anti-O-GlcNAc antibody, we observed no
substantial difference in globalO-GlcNAc levels between the
controls and patients (Fig. 3, A and B). To verify the speci-
ficity of this O-GlcNAc antibody, cell lysates were treated
with a bacterial O-GlcNAcase from Clostridium perfringens
(CpOGA), leading to a loss of O-GlcNAc signal compared
with untreated lysates (Fig. 3A). As an independent control
experiment, we applied a recently developed method to
detect O-GlcNAcylated proteins, which relies on detection
using a tagged inactive bacterial O-GlcNAcase (D298N-
CpOGA) (32). In this experiment, no substantial differences
were observed in global O-GlcNAc levels in fibroblasts
derived from patients versus healthy controls (Fig. 3, C
and D).
We next investigated the effects of the OGTmutations on
levels of OGT and OGA mRNA and protein. Gene expres-
sion levels of OGT and OGA appeared to be unaffected in
patient fibroblasts compared with those of the controls (Fig.
4A). Although OGT protein levels appeared reduced in both
patients compared with the healthy controls (Fig. 4, B andC),
there was considerable variability in OGT protein levels of
the healthy controls (Fig. 4, B andC). At the mRNA level, two
OGT variants (corresponding to WT and mis-spliced prod-
Table 1
Comparison of clinical features of patients with hemizygoteOGTmutations
Patient 1 Patient 2 Niranjan et al. (30) Bouazzi et al. (29)
Genotype
Genomic change (ChrX, GRCh38) 71,555,312GC 71,544,561TG 71,555,223GT 71,555,984GA
cDNA (NM_181672.2) 851 GC 463–466 TG 762 GT 955 GA
Protein R284P L254F A319T
Phenotype
Neurological features
Intellectual disability    
Developmental delay   NDa 
Psychomotor retardation   ND 
Behavioral problems   ND 
Brain abnormalities   ND 
Cardiac symptoms   ND 
Dysmorphic features   ND 
Eye abnormalities   ND 
Genital/reproductive abnormalities   ND 
aND, not determined.
OGT variants in XLID
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ucts) were present for patient 2 (Fig. 2B). However, at the
protein level, comparative analysis with recombinantly
expressed 155–177-OGT (Fig. 4F) did not show evidence
for presence of a truncated OGT protein, suggesting that
155–177-OGT may be unstable/degraded in the context of
these patient fibroblasts. There was a reduction in OGA pro-
tein levels, although again variability was observed in OGA
protein levels of the healthy controls (Fig. 4, D and E). Thus,
OGTmutationsmay lead to reduced functional OGT protein
levels in patient-derived fibroblasts, which may be compen-
sated for with down-regulation of OGA protein levels,
thereby maintaining global O-GlcNAc levels.
Figure 2. Genetic analysis of hemizygous OGT mutations detected in patients with intellectual disability syndrome. A, location of known and newly
discoveredgenetic variants in theOGTgene and their presence in families 1 and2. B, RT-PCR in skin-derived fibroblasts frompatient 2 bearing the c.463–6TG
mutation confirmed by sequence analysis. C, domain organization in human O-GlcNAc transferase. TLR, tetratricopeptide-like repeat. D, model for the full-
length human O-GlcNAc transferase generated by superposition of crystallographic models for the human O-GlcNAc transferase catalytic domain (Protein
Data Bank code 5V1D) and tetratricopeptide repeat domain (Protein Data Bank code 1W3B). Blue represents tetratricopeptide repeats, yellow represents
tetratricopeptide-like repeat, and pink represents catalytic core.
OGT variants in XLID
12624 J. Biol. Chem. (2017) 292(30) 12621–12631
 at RA
D
BO
U
D
 U
N
IV
ERSITEIT N
IJM
EG
EN
 on July 10, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Recombinantmutant OGT is unstable and defective in
HCF-1 processing
The absence of the truncated OGT in patient 2 and potential
reductions in OGT protein levels in patient-derived fibroblasts
suggest that the mutations may compromise OGT stability. To
further investigate this, stability of recombinant wild-type/mu-
tant OGT TPR domain was analyzed by thermal denaturation
experiments. We observed reduced stability for 155–177-
OGT (Tm  51  1 °C) and R284P-OGT (Tm  52  1 °C)
compared with wild-type OGT TPR domain (Tm 59 1 °C)
(Fig. 5A). Given that 155–177-OGT was not detected in
patient-derived fibroblasts, further biochemical characteriza-
tion of this mutant was omitted. OGT has over 1000
O-GlcNAcylation substrates; therefore, to explore the effects of
the p.Arg284Pro mutation in an environment similar to that of
cell physiology, de-O-GlcNAcylated HEK-293 cell lysate was
employed as a complex array of substrates. R284P-OGT was
not able to restore protein O-GlcNAcylation, to the extent
achieved by wild-type OGT (Fig. 5B).
OGT is known to possess a second catalytic activity, promot-
ing autocatalytic cleavage and activation of the transcriptional
co-regulator HCF1, itself an XLID gene (33, 34), via an inter-
mediate glycosylation step (13, 35). Thus, we decided to inves-
tigate the effects of the p.Arg284Pro substitution on OGT-me-
diated HCF1 processing. To measure proteolytic activity, we
used a GST fusion of a minimal HCF1 fragment (HCF1-rep1)
Table 2
Predictionofpathogenicityofdenovomutationsdetected inpatient 1
BRD1 p.Val230Leu OGT p.Arg284Pro
Align GVGD Class C0 Class C35
SIFT Tolerated (score 0.06) Deleterious (score 0.01)
MutationTaster Disease causing (p value: 1) Disease causing (p value: 1)
Polyphen-2 Possibly damaging
(score: 0.544)
Probably damaging
(score: 0.961)
Figure 3. Characterization of global O-GlcNAc levels in patient-derived
skin fibroblasts. A, immunoblot showing global O-GlcNAc levels in patient-
derived fibroblasts detected using RL2 anti O-GlcNAc antibody. C, control; P,
patient. B, the scatter plot indicates fractional ratio of any given actin-normal-
ized signal averaged from three biological replicates, with the error bars rep-
resenting the standard deviation. p values (Mann–Whitney U test): C1–P1
0.4; C1–P2  0.1; C2–P1  0.4; C2–P2  0.9. Achieved power (1   error
probability) 0.1. C, immunoblot showing globalO-GlcNAc levels in patient-
derived fibroblasts detected using the far Western method. The far Western
method relies on detection of O-GlcNAcylated protein using a point mutant
of a Halo-tagged bacterial O-GlcNAcase homolog, CpOGAD298N, as a probe
(32). Halo antibody was used to detect the bands where the probe was local-
ized. D, the scatter plot indicates the fractional ratio of any given actin-nor-
malized signal averaged from three biological replicates, with the error bars
representing the standard deviation. p values (Mann–Whitney U test):
C1–P1 0.9; C1–P2 0.7; C2–P1 0.7; C2–P2 0.9. Achieved power (1 
error probability) 0.1.
Figure4. CharacterizationofOGTandOGA levels inpatient-derived skin
fibroblasts. A, gene expression of OGT and OGA in patient fibroblasts mea-
sured by qPCR. Scatter plots represent mean data from two independent
experiments. Gene expression was calculated according to C(t) method.
Tubulin expression was used as reference, and the data were normalized
against control 1. B, immunoblot showing O-GlcNAc transferase (OGT) levels
in patient-derived fibroblasts. C, control; P, patient. C, the scatter plot indi-
cates fractional ratio of any given tubulin-normalized signal averaged from
threebiological replicates,with the error bars representing the standarddevi-
ation.p values (Mann–WhitneyU test):C1–P1 0.9;C1–P2 0.1;C2–P1 0.9;
C2–P2 0.7. Achieved power (1  error probability) 0.1. D, immunoblot
showing O-GlcNAcase (OGA) levels in patient-derived fibroblasts. E, the scat-
ter plot indicates fractional ratio of any given tubulin-normalized signal aver-
aged from three biological replicates, with the error bars representing the
standard deviation. p values (Mann–Whitney U test): C1–P1  0.2; C1–P2 
0.2;C2–P1 0.2;C2–P2 0.2. Achieved power (1 error probability) 0.1.
F, immunoblot comparingOGT proteinmolecular weight, as present in fibro-
blasts of patient 2 (155–177) andof recombinantly expressedwild-typeOGT
(W) and 155–177-OGT ().
OGT variants in XLID
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possessing the first of the PRO repeats (which are the target
sites of proteolysis; Fig. 5C).Wild-type OGTwas able to hyper-
glycosylate HCF1-rep1, as evidenced by a band shift that was
reversible by incubation with CpOGA (Fig. 5D). The HCF1-
rep1 band shift observed in the R284P-OGT-catalyzed reaction
was smaller, suggesting that the mutant OGT was less effective
than the wild type in glycosylating HCF1-rep1 (Fig. 5D). Fur-
thermore, wild-type OGT was able to induce autoproteolysis,
whereas the proteolytic activity of R284P-OGT was reduced
(Fig. 5D).When the enzyme concentrationwas reduced relative
to substrate levels, proteolytic activity of R284P-OGT was
abrogated, whereas wild-type enzyme still displayed detectable
activity (Fig. 5E). Thus, recombinant R284P-OGT is defective
in HCF1 glycosylation and proteolytic processing.
Discussion
Here, we report two patients with XLID attributable to
hemizygous mutations in OGT: one missense mutation
(p.Arg284Pro) and one splice-site mutation (c.463–6TG).
We identified potential perturbations in protein O-GlcNAc
homeostasis in both patients and altered HCF1 maturation in
patient 1.
XLID is a genetically and phenotypically heterogeneous
group of disorders, estimated to account for10% of all intel-
lectual disability phenotypes in males (36). Mutations causing
XLID have been reported in over 100 genes, and new XLID
genes are still being identified (37). In 2015, Niranjan et al. (30)
published a series of 65 potential XLID genes, by sequencing
the X-exome of 56 XLID families. This was the first publication
in which a genetic variant in OGT (p.Leu254Phe) was found
associated with XLID. During the course of our work, Vaidy-
anathan et al. (38) reported a study on the functional character-
ization of this previously published p.Leu254Phe variant of
OGT (30). In patient-derived lymphoblastoid cells, decreased
OGT levelswere accompanied by decreasedOGA levels, result-
ing in unalteredO-GlcNAc levels. This is in agreementwith our
findings in both patient-derived fibroblast cell lines, indicating
that homeostasis ofO-GlcNAc levels through decreasing OGA
could be a general principle in cases of OGT deficiency. How-
ever, in contrast to our results, recombinantly expressed
p.Leu254Phe OGT and wild-type OGT showed equal activity
toward O-GlcNAc substrate CK2 and HCF-1 (38). Another
study described a missense mutation in OGT (p.Ala319Thr) in
an XLID family, although this mutant also segregated with a
Figure 5. In vitro analysis of recombinantly expressedmutant OGT forms. A, thermal denaturing curve showing fraction of unfolded wild-type (TPR-WT),
R284P (TPR-R284P), and155–177 (TPR-155–177) OGT TPR domains as a function of time. The data were fitted to Boltzmann sigmoidal curve equation. Error
bars represent standard error of mean of seven replicates, and the plot is representative of three biological replicates. B, immunoblot showing the relative
O-GlcNAcylation activities of wild-type OGT (W) and R284P-OGT (R) against de-O-GlcNAcylated HEK-293 lysate. C, domain organization of human HCF1
compared with its truncated form fused to N-terminal GST tag and C-terminal His tag (HCF1-rep1), which was used as a substrate for OGT proteolytic activity.
D, immunoblot showing the relative proteolytic activities of wild-type OGT (W) and R284P-OGT (R) against HCF1-rep1. The samples were treated with an
O-GlcNAcase homolog from C. perfringens (CpOGA) either toward the end of the reaction () or from the beginning (). Closed circle, unprocessed HCF-
1rep1; closed square, HCF1-rep1 cleavage product. E, kinetic assay of the proteolytic activity of wild-type OGT and R284P-OGT against HCF1-rep1 plotted as
amount of product formed as a function of time. Error bars represent standard error of mean of four replicates. The data were fitted to hyperbolic curve
equation.
OGT variants in XLID
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previously uncharacterized variant of MED12, another gene
that is associated with XLID. Evidence for functional loss of
OGT for this mutation was not provided (29).
To date, including our findings, four hemizygous mutations
in OGT have been identified in patients with XLID (Table 1).
The threemissensemutations (p.Arg284Pro, p.Leu254Phe, and
p.Ala319Thr) and one splice-site mutation (c.463–6TG) all
affect the N-terminal TPR domain (Fig. 2C and supplemental
Fig. S1). The TPRmotif is characterized by a repeat of 34 amino
acids that fold into two antiparallel helices. The TPR domain
consists of 13.5 repeats, and the antiparallel helices align to
form an elongated superhelix, where the first helix of each TPR
repeat (helix A) faces toward the inner surface of the elongated
superhelix and their antiparallel pairs (helix B) form the
outer surface (11). The missense mutations p.Arg284Pro,
p.Leu254Phe, and p.Ala319Thr are located in helix B of the
OGTTPR7, TPR8, and TPR9, respectively (Fig. 2D and supple-
mental Fig. S1). In addition, Ala-319 is one of the conserved
hydrophobic amino acid residues of the canonical TPR
repeat (39) (supplemental Fig. S1). Each of these missense
mutations could disrupt the -helical secondary structure of
the TPR domain, thereby affecting the overall stability of the
elongated superhelix (Fig. 2D). Arg-284 is located in the
middle of TPR helix 7B, and mutation of this residue to a Pro
likely disrupts this secondary structure element, destabiliz-
ing this region.
The splice-site mutation c.463–6TG is predicted to result
in an OGT protein missing 23 amino acids (p.155–177) (Fig.
2B), although we could not confirm the presence of a truncated
OGT inpatient fibroblasts (Fig. 4F).Wepropose that thismuta-
tion might exert its effect by producing an unstable splice var-
iant and reducing the amount of functionalOGTwithin the cell
(Figs. 4B and 5A). Global O-GlcNAc levels in patient-derived
fibroblasts were not substantially reduced compared with
healthy controls (Fig. 3). Protein levels of OGT and OGA
appeared to be reduced in both patients; however, both healthy
controls displayed variation in their OGT and OGA levels,
complicating the interpretation of these findings. We hypoth-
esize that the decrease in OGT protein levels in these cells
might be counteracted by the concomitant reduction of OGA
protein levels (Fig. 4, D and E), thereby sustaining basal
O-GlcNAc homeostasis. This hypothesis is supported by the
finding that chemical inhibition ofOGA in different human cell
lines leads to a decreased expression of OGT and an increased
expression of OGA (18), which indicates an as-yet-unidentified
mechanism of regulation to maintain global O-GlcNAc home-
ostasis.Wepropose a similarmechanism in our patient-derived
fibroblasts.
It is as yet not fully understood howOGT recognizes serines/
threonines on specific proteins forO-GlcNAcylation, although
there is evidence to suggest that the TPRs play a key role for at
least a subset of substrates (40). To assess the in vitro activity of
OGTwith mutations affecting the TPR domain and the impact
on substrate O-GlcNAcylation, we produced recombinant
R284P-OGT. Given that 155–177-OGT was not detected in
patient-derived fibroblasts, further biochemical characteriza-
tion of this mutant was not undertaken. Activity assays against
de-O-GlcNAcylated HEK-293 lysate demonstrated that the
p.Arg284Pro mutation led to a global reduction in protein
O-GlcNAcylation, as opposed to reducing recognition and
O-GlcNAcylation of specific substrates. In a physiological con-
text, this nonspecific reduction inOGT activitymay be rescued
by down-regulation ofOGA levels, whichwas observed to some
extent in the fibroblasts from both patients. However, the
p.Arg284Pro mutation is located on the surface of the TPRs
(11), a region that has been shown to play a role in the recogni-
tion of specific substrates (40). It is therefore possible that this
mutation could affect modification of specific substrates, in
addition to causing the observed global reduction in substrate
O-GlcNAcylation, and this possibility is neither excluded nor
confirmed by our current data. O-GlcNAcylation activity of
R284P-OGT against HCF1-rep1 was reduced, as judged by the
poly-O-GlcNAcylation-induced shift in HCF1-rep1 molecular
weight versus wild-type OGT (Fig. 5D).
In addition to being abundantlyO-GlcNAcylated (15), HCF1
is also proteolytically processed by OGT (12, 35). The
p.Arg284Pro mutation appears to alter HCF1-rep1 proteolysis
in vitro (Fig. 5,D and E). The TPR domain is critical for proteo-
lytic maturation of HCF1 (13), and this could explain why
R284P-OGT shows decreased proteolytic activity toward
HCF1 in vitro. Interestingly, HCFC1, the gene that codes for
HCF1, is located on the X-chromosome, and it is reported as an
XLID gene (41). This hints at possible overlap in downstream
disease mechanisms causing intellectual disability in patients
bearing OGT or HCFC1 mutations.
Precisely how alterations in protein O-GlcNAcylation and
HCF1 cleavage lead to intellectual disability is not yet clear.
OGT is expressed in a broad range of tissues, with a remarkably
high expression in brain (9, 10). O-GlcNAc-modified proteins
were detected in nerve terminals, and abundant OGT activity
was detected in nerve synaptosomes (42), indicating that
O-GlcNAc could play a role in neuronal function and neurode-
generative disease. It has been suggested that regulation of the
proteasome complex by O-GlcNAcylation in the brain could
contribute to apoptosis of hippocampal cells and thus neurode-
generation (43). In addition, aberrant O-GlcNAcylation levels
have been linked to neurodegenerative diseases like Alzhei-
mer’s disease (28). Future work analyzing the effect of XLID
mutations on OGT function in a more phenotype-relevant
model, such as a neuronal cell line or an animal model where
the effect of the mutations on different tissues, including the
brain, can be investigated, would be important. The present
study utilized fibroblasts from twounrelated individuals as con-
trols, and we noted substantial variability in OGA and OGT
protein levels in these cells, complicating the interpretation of
our data. Tominimize the effect of variability introduced by the
differing genetic background between individual patients and
controls, it would be of use to introduce these mutations into
cell lines with an identical genetic background. Our study pro-
vides the first detailed clinical characterization of patients with
XLID attributable to mutations in OGT and furthermore pro-
poses a potential molecular explanation for how these muta-
tions may impact on OGT dual function of O-GlcNAcylation
and HCF1 proteolysis.
OGT variants in XLID
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Experimental procedures
Patient consent
The study was approved by the Institutional Review Board at
Radboud University Medical Centre and Utrecht University
Medical Centre. All participating affected individuals or their
legal representatives gave informed consent for exome
sequencing and to publication of this study. Fibroblasts of the
patients were obtained for diagnostics of inborn errors of
metabolism and used after informed consent from parents
and/or treating physicians, in accordance with the Declaration
of Helsinki. For use of facial images, written informed consent
was obtained.
Whole exome sequencing
For patient 1, whole exome sequencing was performed in a
trio diagnostic approach as described before (44). Exome cap-
ture was performed with the SureSelect Human All Exon v4
enrichment kit (Agilent, Santa Clara, CA). Whole exome
sequencingwas performedon the IlluminaHiSeqplatform (San
Diego,CA).Datawere analyzedwith theBWA(read alignment)
and GATK (variant calling) software packages. Variants were
annotated using an in-house developed pipeline. Prioritization
of variantswas done by an in-house designed “variant interface”
and manual curation.
Exomes of patient 2 and parents were enriched using the
SureSelect XTHumanAll Exon V5 kit (Agilent) and sequenced
in rapid run mode on the HiSeq2500 sequencing system (Illu-
mina) at a mean target depth of 100	. The target is defined as
all coding exons of UCSC and Ensembl 20-bp intron flanks.
At this depth 95% of the target is covered at least 15 times.
Reads were aligned to hg19 using BWA (BWA-MEM v0.7.5a),
and variantswere called using theGATKhaplotype caller (v2.7-
2). Detected variants were annotated, filtered, and prioritized
using the Bench NGS Lab platform (Cartagenia; Agilent). The
OGT gene sequences of the grandmother and great-grand-
mother were analyzed to study the origin of the mutation. All
potentially causative variants were confirmed by Sanger
sequencing.
Cell culture
Skin fibroblasts derived from patients and healthy donors
were cultured at 37 °C under 5.0% CO2 inM199medium (PAN
Biotech, Aidenbach, Germany) or Dulbecco’s modified Eagle’s
medium (Thermo Fisher Scientific) containing 2 mM L-gluta-
mine (Sigma). Media were supplemented with 10% fetal calf
serum (Labtech, Uckfield, UK) and 1% penicillin-streptomycin
(Thermo Fisher Scientific).
RNA extraction, cDNA synthesis, and quantitative RT-PCR
Total cell RNA was extracted from skin fibroblasts using
TRIzol reagent (Thermo Fisher Scientific). cDNA was synthe-
sized with a RevertAid First Strand cDNA synthesis kit
(Thermo Fisher Scientific) using randomhexamer primers. For
quantification of OGT andOGA expression levels, cDNA from
skin fibroblasts was mixed with GoTaq qPCR Master Mix
(Promega) and both forward and reverse primers. Tubulin
expression was used as an internal control. All qPCR experi-
ments were conducted at Bio-Rad CFX96 real-time system fol-
lowing the GoTaq qPCR Master Mix manual. Specificity of
the reactions was verified withmelt curve analysis. The primers
used are listed in supplemental Table S1. For analysis of OGT
mRNA splicing in skin fibroblaststk;1 of patient 2, cDNA and
primers were mixed with AmpliTaq Gold 360 Master Mix
(Thermo Fisher Scientific). RT-PCR was conducted accord-
ing to standard conditions and PCR products were purified
using a QIAquick gel extraction kit (Qiagen). Purified PCR
products were used for sequencing analysis.
Biochemical characterization of patient-derived fibroblasts
Patient-derived fibroblasts were grown on 15-cm plates and
were washed twice with ice-cold PBS buffer (Thermo Fisher
Scientific) prior to lysis. The cells were lysed by addition of lysis
buffer (50 mM Tris-HCl, pH 7.4, 1 mM EGTA, 1 mM EDTA, 1%
TritonX-100, 1mMNa3VO4, 50mMNaF, 5mMpyrophosphate,
0.27M sucrose) supplementedwith 1MGlcNAcstatin-G, 1M
-mercaptoethanol, and protease inhibitormixture (1mMben-
zamidine, 0.2mMPMSF, 5mM leupeptin). The lysate was trans-
ferred into an Eppendorf and clarified by centrifugation at 4 °C
(1200 	 g for 15 min). Lysate proteins were resolved by SDS-
PAGE (4–12% acrylamide; Thermo Fisher Scientific) and
transferred onto nitrocellulose membranes (GE Healthcare).
Analysis of O-GlcNAcylated fibroblast proteins by the far
Western method was performed as described previously (32).
Briefly, soluble cell lysates were prepared, resolved by SDS-
PAGE (3–8%Tris acetate; Thermo Fisher Scientific) and trans-
ferred onto nitrocellulose membranes (GE Healthcare) as
described above, but with lysis buffer lacking GlcNAcstatin-G.
Protein expression and purification
Full-length wild-type OGT and mutants (R284P and 155–
177)were expressed inEscherichia coli asN-terminalHis fusion
proteins as described previously (45). The wild-type OGT TPR
domain (residues 26–420) andmutants (TPR-R284P andTPR-
155–177)were expressed and purified as described previously
(11).HCF1-rep1 (residues 867–1071)was expressed inE. coli as
a non-cleavable N-terminal GST and C-terminal His fusion
protein. Transformed BL21 (DE3) cells were grown, induced
for expression, lysed, and clarified as described previously (45).
Clarified lysate was incubated with 1 ml/liter of culture of glu-
tathione-Sepharose 4B resin (GE Healthcare) for 2 h at 4 °C.
The resin was thoroughly washed with base buffer (0.1 M Tris-
HCl, pH7.5, 150mMNaCl, 0.5mMTCEP) and eluted using base
buffer supplementedwith 0.5 M glutathione. Eluted protein was
dialyzed overnight at 4 °C in bufferA (0.1MTris-HCl, pH7.5, 25
mMNaCl). Dialyzed protein was passed through 5ml ofHiTrap
Q-Sepharose FF anion exchange resin (GEHealthcare), collect-
ing the flow-through, which was then concentrated and passed
through a 300-ml SuperdexTM 200 column (GE Healthcare)
pre-equilibrated with base buffer. The peak fractions were con-
centrated to 10 mg/ml, mixed 1:1 with 50% glycerol, snap-fro-
zen, and stored at80 °C until use.
Molecular cloning
The fragment of HCF1-rep1 (residues 867–1071) was
obtained fromMVPhuman total brain RNA fromAgilent using
OGT variants in XLID
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the Takara PrimeScript high-fidelity RT-PCR kit. The reverse
primer coded for theC-terminal addition of aHis6 tag. ThePCR
product was cloned as a BamHI-NotI fragment into a mutated
version of pGEX6P1, which lacks the PreScission protease site.
The full-length codon optimizedOGTwas obtained fromGen-
Script and subcloned as a BamHI-NotI fragment into pHEX6P1
(modified version of pGEX6P1 which contains a His6 tag
instead of GST). The R284P and the155–177mutations were
introduced using a method similar to the QuikChange site-
directed mutagenesis kit (Agilent) but using KOD polymerase
and DpnI from Fermentas. All inserts were confirmed by DNA
sequencing.
Thermal denaturing assay
Thermal denaturing experiments were performed in tripli-
cate, using the OGT TPR domain constructs. 50-l solutions
contained 5 M protein and 1.1x SYPROOrange dye (Sigma)
in base buffer of 25 mM HEPES-NaOH, pH 7.5, 150 mM NaCl,
and 0.5 mM TCEP. A Bio-Rad (CFX ConnectTM real-time sys-
tem was used to measure fluorescence (ex  530 nm, em 
560 nm) while temperature was increased from 25 to 95 °C at
1°/min increments. The data were transformed, normalized,
and fitted to a Boltzmann sigmoidal curve using GraphPad
Prism 5.0.
In vitro O-GlcNAcylation assay
O-GlcNAcylation assays were performed in triplicate on
de-O-GlcNAcylated HEK-293 lysate proteins. HEK-293 cell
lysates were prepared as described for patient-derived fibro-
blasts, but with the lysis buffer lacking GlcNAcstatin-G. HEK-
293 lysate was treated with 120 g of CpOGA per mg of lysate
protein and incubated for 90min at 37 °C.CpOGAwas neutral-
ized by the addition of 250MGlcNAcstatin-G. Reactions were
supplemented with wild-type OGT or R284P-OGT (0.2 M) in
the presence of 2 mM UDP-GlcNAc and incubated for an addi-
tional 2 h at 37 °C. Proteins were resolved by SDS-PAGE (3–8%
acrylamide; Thermo Fisher Scientific) and transferred onto
nitrocellulose membrane (GE Healthcare).
In vitro proteolytic assay
Proteolytic assays were performed using HCF1-rep1 (resi-
dues 867–1071) with GST and His tags at the N and C termini,
respectively. For qualitative measurement of proteolytic activ-
ity, HCF1-rep1 (2.5 M), preincubated or not with CpOGA (5
M), was combinedwith wild-typeOGTor R284P-OGT (1M)
in the presence of 1 mMUDP-GlcNAc. Reactionmixtures were
incubated at 37 °C for 8 h with gentle agitation, followed by
optional addition ofCpOGA.Mixtures were incubated at 37 °C
for an additional 1 h, before stopping the reaction by addition of
LDS loading buffer (4	) (Thermo Fisher Scientific). Proteins
were resolved by SDS-PAGE (4–12% acrylamide; Life Technol-
ogies) and transferred onto nitrocellulose membranes (GE
Healthcare). Initial velocity for OGT-catalyzed proteolysis of
HCF1-rep1 was measured in triplicate. HCF1-rep1 (1.5 M)
was combinedwithwild-typeOGTorR284P-OGT (0.15M) in
the presence of 150 M UDP-GlcNAc. Reaction mixtures were
incubated at 37 °C with gentle agitation, whereas aliquots were
taken out at the designated time points (0, 0.5, 1, 2, 4, 8, 16, and
32 h) and stopped by mixing with LDS loading buffer (4	)
(Thermo Fisher Scientific). The initial volume of the reaction
was 90l, and 2.5-l aliquotswere loaded in each lane. Proteins
were resolved by SDS-PAGE (10% acrylamide) and visualized
by Coomassie staining. The amount of product formed was
quantified using a LI-COR Odyssey scanner and associated
quantification software. The data were background-corrected
and plotted using GraphPad Prism 5.0.
Immunoblots
Membranes were probed with following primary antibodies:
O-GlcNAc (RL2; Abcam, Cambridge, UK), actin (Sigma), OGT
(H300; Santa Cruz), OGA (14711-1-AP; Proteintech, Rose-
mont, IL), tubulin (Cell Signaling), HSP-90 (Cell Signaling), and
GST-S902 (Division of Signal Transduction Therapy, Univer-
sity of Dundee). In case of the farWesternmethod, membranes
were probed with 10 g/ml Halo-tagged CpOGA and incu-
bated with halo primary antibody (Promega). Subsequently all
membranes were incubated with IR680- or IR800-labeled sec-
ondary antibodies (LI-COR) and analyzed using a LI-COR
Odyssey scanner and associated quantification software. All
primary and secondary antibodies were used in 1:5,000 and
1:10,000 dilutions, respectively.
Data analysis
Scatter plots indicate ratios of any given normalized signal as
averaged from three biological replicates, with the error bars
representing standard deviation. Variations in data were calcu-
lated by Mann–Whitney U test using GraphPad Prism 5.0.
Power calculations were performed using G*Power 3.1.
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Fig. S1. Sequence alignment of TPRs 
A.    Sequence alignment of the 13.5 human OGT TPRs. Blue and red cylinders annotate the 
first helix (helix A) and its antiparallel pair (helix B) within each TPR motif, 
respectively. The alignment is coloured in grayscale based on sequence conservation. The 
regions affected by all four XLID mutations, Δ155-177, Leu254Phe, Arg284Pro and 
Ala319Thr, are highlighted in pink colour.  
B.    Sequence alignment of OGT exon 7 from various metazoan species. Blue and red 
cylinders annotate the first helix (helix A) and its antiparallel pair (helix B) within each 
TPR motif, respectively. The alignment is coloured in grayscale based on sequence 
conservation. The XLID mutations  Leu254Phe and Arg284Pro are highlighted in pink 
colour.  
C.    Sequence alignment of OGT exon 8 from various metazoan species. Blue and red 
cylinders annotate the first helix (helix A) and its antiparallel pair (helix B) within each 
TPR motif, respectively. The alignment is coloured in grayscale based on sequence 
conservation. The XLID mutation Ala319Thr is highlighted in pink colour.  
  
Table S1: Overview of used primers 
 
Analysis of mRNA expression by qPCR 
 OGT (Fw) 5’- GCCAGCTCCTATTCAGGCAA -3’ 
OGT (Rv) 5’- CCATGAAAAGCGCACCACTC -3’ 
OGA (Fw) 5’- TGCGATCTCACCTGGATTGG -3’ 
OGA (Rv) 5’- CCAAACTGAGAAACCTGGTCC -3’ 
Tubulin (Fw) 5’- CAATGAAGCCACAGGTGGCAAA -3’ 
Tubulin (Rv) 5’- GTTGTTACCTGCCCCAGACT-3’ 
  Analysis of OGT mRNA splicing  
 Fw 5’- GCATTGCGTCTCAAACCTGA-3’ 
Rv 5’- AAGCCAAATTTCCCCTTGTGC-3’ 
  Molecular cloning 
 hOGT_R284P_fwd GCTATTGATACCTATCGTCcgGCGATTGAACTGCAGCCG 
hOGT_R284P_rev CGGCTGCAGTTCAATCGCcgGACGATAGGTATCAATAGC 
hOGT_delta_155_177_fwd gtctctgcgctgcagtataacccggcctgttacctgaaagcgattgaaacc 
hOGT_delta_155_177_rev ggtttcaatcgctttcagg taacaggccgggttatactgcagcgcagagac 
HCF_fwd aaaGGATCCccagccgtcaccacgttggttgtg 
HCF_rev aaaGCGGCCGCttaGTGGTGATGATGGTGATGcacgctaccattctgctggcccac 
 
